NO330136B1 - Slankende kosmetisk preparat - Google Patents
Slankende kosmetisk preparat Download PDFInfo
- Publication number
- NO330136B1 NO330136B1 NO20022144A NO20022144A NO330136B1 NO 330136 B1 NO330136 B1 NO 330136B1 NO 20022144 A NO20022144 A NO 20022144A NO 20022144 A NO20022144 A NO 20022144A NO 330136 B1 NO330136 B1 NO 330136B1
- Authority
- NO
- Norway
- Prior art keywords
- adipocytes
- substance
- preparation
- component
- slimming
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims description 14
- 210000001789 adipocyte Anatomy 0.000 claims description 66
- 238000002360 preparation method Methods 0.000 claims description 47
- 108090001005 Interleukin-6 Proteins 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 238000000855 fermentation Methods 0.000 claims description 7
- 230000004151 fermentation Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 claims description 3
- 241000194108 Bacillus licheniformis Species 0.000 claims description 2
- 241000223252 Rhodotorula Species 0.000 claims description 2
- 241000187747 Streptomyces Species 0.000 claims description 2
- 239000000126 substance Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 26
- 102000004889 Interleukin-6 Human genes 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 210000004003 subcutaneous fat Anatomy 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 11
- 239000013543 active substance Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000011835 investigation Methods 0.000 description 8
- 102000016267 Leptin Human genes 0.000 description 7
- 108010092277 Leptin Proteins 0.000 description 7
- 229940039781 leptin Drugs 0.000 description 7
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 7
- 210000000229 preadipocyte Anatomy 0.000 description 7
- 230000007115 recruitment Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 206010033675 panniculitis Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101710151321 Melanostatin Proteins 0.000 description 4
- 102400000064 Neuropeptide Y Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003076 paracrine Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- -1 however Proteins 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000003919 adipocyte function Effects 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003243 anti-lipolytic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000008003 autocrine effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000487 effect on differentiation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000003207 subcutaneous adipocyte Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000576 supplementary effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002666 vasoprotective effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9913917A FR2800610B1 (fr) | 1999-11-05 | 1999-11-05 | Composition cosmetique amincissante contenant une substance inducteur de la production d'il-6 |
| PCT/FR2000/003048 WO2001032137A1 (fr) | 1999-11-05 | 2000-11-02 | Composition amincissante contentant une substance inducteur de la production d'il-6 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20022144D0 NO20022144D0 (no) | 2002-05-03 |
| NO20022144L NO20022144L (no) | 2002-06-20 |
| NO330136B1 true NO330136B1 (no) | 2011-02-21 |
Family
ID=9551783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20022144A NO330136B1 (no) | 1999-11-05 | 2002-05-03 | Slankende kosmetisk preparat |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20050281895A1 (xx) |
| EP (1) | EP1229895B1 (xx) |
| JP (1) | JP2003513029A (xx) |
| KR (1) | KR20020063887A (xx) |
| CN (1) | CN1236757C (xx) |
| AR (1) | AR026349A1 (xx) |
| AT (1) | ATE537810T1 (xx) |
| AU (1) | AU782931B2 (xx) |
| BR (1) | BR0015323A (xx) |
| CA (1) | CA2390129C (xx) |
| CO (1) | CO5271719A1 (xx) |
| ES (1) | ES2379768T3 (xx) |
| FR (1) | FR2800610B1 (xx) |
| HK (1) | HK1046855A1 (xx) |
| HR (1) | HRP20020390A2 (xx) |
| HU (1) | HU229027B1 (xx) |
| IL (2) | IL149338A0 (xx) |
| MX (1) | MXPA02004518A (xx) |
| NO (1) | NO330136B1 (xx) |
| PL (1) | PL201755B1 (xx) |
| RU (1) | RU2258500C2 (xx) |
| TR (1) | TR200201214T2 (xx) |
| TW (1) | TWI253938B (xx) |
| UY (1) | UY26428A1 (xx) |
| WO (1) | WO2001032137A1 (xx) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7323162B2 (en) * | 2002-12-27 | 2008-01-29 | Avon Products, Inc. | Aqueous cosmetic coloring and gloss compositions having film formers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3793153A (en) * | 1970-06-06 | 1974-02-19 | Y Miura | Method for propagating yeasts and molds by mixed culturing and method of fermentation thereof |
| FR2669537B1 (fr) * | 1990-11-28 | 1993-02-19 | Oreal | Composition amincissante a base d'alpha-2-bloqueurs. |
| FR2714598B1 (fr) * | 1993-12-30 | 1996-02-09 | Oreal | Composition amincissante à deux types de liposomes pour traitement topique, son utilisation. |
| FR2754709B1 (fr) * | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
| FR2758724B1 (fr) * | 1997-01-24 | 1999-04-23 | Javenech | Composition topique a base de protamine pour le traitement de la cellulite et des surcharges ponderales |
| FR2774695B1 (fr) * | 1998-02-11 | 2002-06-14 | Sanofi Sa | Composition cosmetique contenant un compose a activite stimulatrice de la production d'interleukine-6 |
-
1999
- 1999-11-05 FR FR9913917A patent/FR2800610B1/fr not_active Expired - Fee Related
-
2000
- 2000-11-02 RU RU2002112243/15A patent/RU2258500C2/ru not_active IP Right Cessation
- 2000-11-02 EP EP00974628A patent/EP1229895B1/fr not_active Expired - Lifetime
- 2000-11-02 KR KR1020027005805A patent/KR20020063887A/ko not_active Application Discontinuation
- 2000-11-02 IL IL14933800A patent/IL149338A0/xx active IP Right Grant
- 2000-11-02 MX MXPA02004518A patent/MXPA02004518A/es active IP Right Grant
- 2000-11-02 AT AT00974628T patent/ATE537810T1/de active
- 2000-11-02 AU AU12859/01A patent/AU782931B2/en not_active Ceased
- 2000-11-02 CA CA2390129A patent/CA2390129C/fr not_active Expired - Fee Related
- 2000-11-02 CN CNB00818187XA patent/CN1236757C/zh not_active Expired - Fee Related
- 2000-11-02 PL PL355259A patent/PL201755B1/pl unknown
- 2000-11-02 BR BR0015323-0A patent/BR0015323A/pt active Search and Examination
- 2000-11-02 HU HU0203910A patent/HU229027B1/hu not_active IP Right Cessation
- 2000-11-02 WO PCT/FR2000/003048 patent/WO2001032137A1/fr active IP Right Grant
- 2000-11-02 ES ES00974628T patent/ES2379768T3/es not_active Expired - Lifetime
- 2000-11-02 JP JP2001534342A patent/JP2003513029A/ja not_active Withdrawn
- 2000-11-02 TR TR2002/01214T patent/TR200201214T2/xx unknown
- 2000-11-02 CO CO00083530A patent/CO5271719A1/es active IP Right Grant
- 2000-11-03 AR ARP000105798A patent/AR026349A1/es not_active Application Discontinuation
- 2000-11-03 UY UY26428A patent/UY26428A1/es not_active IP Right Cessation
- 2000-11-07 TW TW089123286A patent/TWI253938B/zh not_active IP Right Cessation
-
2002
- 2002-04-24 IL IL149338A patent/IL149338A/en not_active IP Right Cessation
- 2002-05-03 HR HR20020390A patent/HRP20020390A2/hr not_active Application Discontinuation
- 2002-05-03 NO NO20022144A patent/NO330136B1/no not_active IP Right Cessation
- 2002-11-20 HK HK02108405.0A patent/HK1046855A1/zh unknown
-
2005
- 2005-07-28 US US11/192,845 patent/US20050281895A1/en not_active Abandoned
-
2008
- 2008-10-28 US US12/259,575 patent/US8628770B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8524204B2 (en) | Cosmetic compositions and methods for inhibiting or reducing trypsin activity | |
| US20110262551A1 (en) | Cosmetic composition | |
| KR102152878B1 (ko) | 락토바실러스 펜토서스 균주 및 이를 포함하는 미생물 균총 개선 및 피부 장벽 개선용 조성물 | |
| JP2012519735A (ja) | 角化細胞のｐａｒ２活性化を阻害するための組成物及び方法 | |
| KR20110057895A (ko) | 진세노사이드 Ｒｅ 및 진세노사이드 화합물 Ｋ를 함유하는 히알루론산 생성 촉진용 피부 외용제 조성물 | |
| KR100955312B1 (ko) | 피토스핑고신의 체중감소제로서의 화장품적 용도 및피토스핑고신을 함유하는 화장품 조성물 | |
| KR102202391B1 (ko) | 상처 치유 및 피부 병변 회복을 위한 알라닌-글루타민, 히알루론산, 귀리 추출물의 상승적 조합 및 조성물로서의 용도 | |
| NO330136B1 (no) | Slankende kosmetisk preparat | |
| JP5719050B2 (ja) | 角化細胞のｐａｒ２活性化を阻害するための組成物及び方法 | |
| KR101149686B1 (ko) | 카테킨류 및 캄페롤 성분을 함유하는 피지억제용 화장료조성물 | |
| KR20140079571A (ko) | 얌빈 추출물을 이용한 피부 외용제 조성물 | |
| KR20200073584A (ko) | 민들레 및 자소엽 추출물을 유효성분으로 함유하는 여드름 완화용 화장료 조성물 | |
| KR20140072419A (ko) | 주름 개선용 조성물 | |
| KR102451466B1 (ko) | 작약 첨가 안티폴루션 발효 식물성 오일, 및 이를 포함하는 화장료 조성물 | |
| KR101056541B1 (ko) | Ｐｐａｒ 알파 활성화제를 함유하는 피부장벽 개선 및 아토피 개선용 조성물 | |
| WO2022055034A1 (ko) | 노르데나우수를 이용한 기능성 화장료 조성물 | |
| KR101602884B1 (ko) | 비타민 ｕ를 유효성분으로 함유하는 슬리밍용 화장료 조성물 | |
| KR20050026297A (ko) | 생약재 추출물을 함유하는 화장료 조성물 및 그 추출 방법 | |
| KR102397975B1 (ko) | 키레놀을 포함하는 피부 보습용 피부외용제 조성물 | |
| CN117815090A (zh) | 长寿基因sirt1的表达促进剂 | |
| KR20230010994A (ko) | 피부의 주름 개선, 미백, 세포 재생, 상처 치유에 유효한 피트 추출물과 소금을 활성성분으로 함유하는 다 기능성 화장품 조성물 | |
| CN117815092A (zh) | 角质形成细胞pparg的表达促进剂 | |
| KR20030024322A (ko) | 피부 탄력 개선제로서 사이클릭아데노신-3',5'-일인산을포함하는 화장료 조성물 | |
| Lee et al. | Anti | |
| KR20170030837A (ko) | 캠토테신을 포함하는 피부 노화 방지용 피부외용제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |